BartelenaL, MarcocciC, BogazziF. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. NEJM1989; 321:1349–52.
2.
BartelenaL, MarcocciC, BogazziF. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. NEJM1998; 338:73–8.
3.
HallP, LundellG, HolmLE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinologica1993; 128(3):230–4.
4.
FranklynJA, MaisonneuveP, SheppardMC. Mortality after treatment with radioactive iodine. NEJM1998; 338(11):712–8.
5.
RonE, DoodyMM, BeckerDV. Cancer mortality following treatment for hyperthyroidism. Cooperative Thyrotoxicosis Therapy Study Group. Comment in JAMA1998; 280(4):375–6.
6.
RosoveMH. Agranulocytosis and antithyroid drugs. West J Med1997; 126:339–43.
7.
VanderpumpMPJ, TunbridgeWMG, FrenchJM. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endo1995; 43:55–68.
8.
FaberJ, GalleoAM, GalleAM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol1994; 130:350–6.
9.
SawinCT, GellerA, WolfPA. Low serum thyrotrophin concentrations as a risk factor for atrial fibrillation in older persons. N Eng J Med1994; 331:1249–52.
10.
KelnarCJH. Endocrine gland disorders and disorders of growth and puberty. In: CampbellAGM, & McIntoshN: Forfar and Arneil's Textbook of Paediatrics: 1998. 5th edn.Churchill Livingstone: Edinburgh. 996–1098.
McGauleyGA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand1989; 356 (Supplement):70–2 (discussion).
13.
RosenT, BengtssonBA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet1990; 336:285–8.
14.
BatesAS, Vann't HoffW, JonesPJ. The effect of hypopituitarism on life expectancy. JCEM1996; 81(3):1169–72.
15.
BagatellCJ, BremnerWJ. Androgen in men – uses and abuses. NEJM1996; 334:707–14.
Barrett-ConnorE. Hormone replacement therapy. Brit Med J1998; 217:457–61.
19.
HulleyS, GradyDBush T et al for the Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998; 280:605–13.
20.
The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/ progestin Interventions Trial. JAMA1995; 273:199–208.
21.
CompstonJE, CooperC, KanisJA. Bone densitometry in clinical practice. Brit Med J1995; 310:1507–10.
22.
RalstonSH. The genetics of osteoporosis. QJM1997; 89:247–51.
23.
Dawson-HughesB, HarrisSS, KrallEA. Effect of calcium and vitamin D supplementation on bone density in men and women over 65 years of age or older. NEJM1997; 337(10):670–6.
24.
CompstonJE. Prevention and management of osteoporosis. Drugs1997; 53:727–35.
25.
EastellR. Treatment of postmenopausal osteoporosis. NEJM1998; 338:736–46.
26.
WillisD, MasonH, Gilling-SmithC. Modulation by insulin of follicle stimulating and lutenising hormone action in human granulosa cells of normal and polycystic ovaries. JCEM1996; 81:302–9.
27.
WaterworthDM, BennettST, GharaniN. Linkage and association of the insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet1997; 349:986–90.
28.
FranksS, GharaniN, WaterworthD. The genetic basis of polycystic ovary syndrome. Lancet1997; 349:986–90.
29.
MontagueC, FarooqiI, WhiteheadJ. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature1997; 387:903–8.
30.
JacksonRS, CreemersJWM, OhagiS. Obesity & impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nature Genetics1997; 16:303–6.
